PRESS RELEASE MASITINIB RECEIVES ORPHAN DRUG STATUS FOR THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS) IN SWITZERLAND Paris, December 27, 2022, 7pm.
27.12.2022 - PRESS RELEASE MASITINIB RECEIVES ORPHAN DRUG STATUS FOR THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS) IN SWITZERLAND Paris, December 27, 2022, 7pm CET AB Science SA (Euronext - FR0010557264 - AB) today announces that masitinib has been . Seite 1
PRESS RELEASE MASITINIB RECEIVES ORPHAN DRUG STATUS FOR THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS IN SWITZERLAND Paris, December 27, 2022, 7pm CET AB Science SA today announces that.
Masitinib receives orphan drug status for the treatment of amyotrophic lateral sclerosis in Switzerland streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.